ESTRO 2024 - Abstract Book

S268

Brachytherapy - Gynaecology

ESTRO 2024

Conclusion:

AGuIX-NP at 50 mg/kg combined with chemoradiation appeared tolerable and yielded to excellent local control. Optimal management use of the radiosensitizing effects may warrant integration of quantification strategies as tool of treatment personalization and radiation use focal adaptation.

Keywords: nanoparticles, cervical cancer, MRI

2327

Proffered Paper

Brachytherapy for recurrent gynecologic tumors: systematic review of reporting patterns

Sabrina Reichl 1 , Ricarda Stella Guninski 1 , Primoz Petric 1,2

1 University Hospital Zürich, Department of Radiation Oncology, Zürich, Switzerland. 2 Aarhus University Hospital, Department of Oncology, Aarhus, Denmark

Purpose/Objective:

Absence of CTV-ITV-PTV margins and steep dose fall-off make gynecological re-irradiation with brachytherapy (GRIB) an excellent modality for selected recurrences. Recent review by the American Brachytherapy Society demonstrated favorable results (1). Since this review, 7 additional retrospective studies have been published (2). Nevertheless, data to guide therapeutic decisions is limited due to scarce publications, small sample sizes, and